Imunon, Inc.: IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its ...
FDA Project Team supports the company's proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint Final Protocol submission ...